Floatz logo

VINBLASTINE

Head and Neck Cancer

Intensity Therapeutics, Inc.Small moleculePhase 1/2Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
73/ 100

Competitive context

114 Active assets in the Head and Neck Cancer cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
ImmunityBio, Inc.
Phase 3BB
Carboplatin
Rapa Therapeutics LLC
Phase 3BB
FILGRASTIM
University of Colorado, Denver
Phase 2BB
Cetuximab
Pfizer
Phase 3BB
Epirubicin
Thomas Jefferson University
Phase 3BB

View all 50 →

Same molecule, other indications

VINBLASTINE is also rated in:

renal pelvis/ureter urothelial carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →
carcinoma of urethraDormant
BBB
Indicative ·
73 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →